Compliance Operations Manager

Mayne Pharma (ASX:MYX) revenue falls 6% in FY26 despite return to statutory profit. 26 August 2026 06:38 PM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key highlights. * FY26 Revenue was $383.7 million, down 6% on FY25, while underlying EBITDA fell 27% to $34.2 million. * Reported Net Profit After Tax was $31.2 million, a turnaround from a $90.1 million loss in FY25, driven by a $125.6 million non-cash earn-out Liability reassessment gain. * Gross Margin expanded 410 basis points to 64.7%, supported by disciplined pricing and portfolio mix. * Cash and marketable securities fell to $80.0 million from $100.4 million, reflecting earn-out payments and Cosette transaction and litigation costs. Mayne Pharma Group Limited (ASX:MYX) reported FY26 revenue of $383.7 million, down 6% on FY25's $408.1 million. Despite the revenue decline, Gross Profit was broadly flat at $248.1 million, with gross margin expanding 410 basis points to 64.7% on what the company described as disciplined pricing, portfolio mix and channel execution. Total direct segment contribution was $107.1 million, down 2% on the prior year. Underlying EBITDA, which excludes earn-out reassessments, litigation and restructuring charges and other one-off items, was $34.2 million, down 27% on FY25's $47.0 million. The company attributed the decline to general Business disruption arising from the Cosette transaction process and subsequent legal matters, combined with a deliberate step-up in Women's Health sales and Marketing Investment during the second half. Statutory profit driven by non-cash earn-out gain. Reported EBITDA was $141.4 million, up 668% on FY25's $18.4 million, while reported Net Profit After Tax was $31.2 million, compared with a $90.1 million loss in FY25, an improvement of $121.3 million. This turnaround was primarily driven by a $125.6 million non-cash gain from the reassessment of an earn-out liability. Operating Cash Flow from continuing operations was $34.5 million, down 24% on FY25, excluding transaction and litigation costs. CEO Aaron Gray said FY26 was a year in which the company strengthened the foundations of the business and positioned it for long-term growth, noting that while the Cosette transaction process and subsequent legal matters placed real demands on management focus and caused general disruption, the company used the year to invest with conviction in its Women's Health sales and promotional capability. Segment performance across Women's Health, dermatology and International. Women's Health revenue was $174.3 million, down 2% on the prior year, with gross profit of $138.0 million, down 3%, and gross margin of 79%, down 1 percentage point. Within the segment, BIJUVA total prescriptions rose 26% with net sales up 20% to US$15.0 million, while NEXTSTELLIS Demand cycles grew 15% with net sales of US$45.2 million, up 6%. ANNOVERA net sales declined 13% to US$25.7 million, which the company attributed to persistent product returns, prompting a shift to alternate sales channels with a more favourable returns profile. Dermatology and DistributeRx segment revenue was $138.7 million, down 10% on the prior year, though gross profit rose 7% to $88.7 million and gross margin expanded 19 percentage points to 64%, delivering direct contribution growth of 11% to $44.5 million despite the lower segment revenue. The company's International segment reported revenue of $70.7 million, down 7%, with gross profit flat at $21.3 million and direct contribution down 38% to $4.6 million, reflecting the transition from lower to higher margin products within the portfolio. DistributeRx launch and Cash position. Mayne Pharma launched DistributeRx, its direct-to-patient distribution platform, in March 2026, with Adelaide Apothecary serving as its licensed pharmacy arm. In its first full quarter, DistributeRx generated 62,000 total prescriptions, an increase of 63% versus the prior comparative period, with new prescriptions increasing 104% to 42,000. On 18 May 2026, the company announced that Adelaide Apothecary will relocate and expand to a new automated Facility in Lexington, Kentucky, lifting capacity to more than 2.5 million prescriptions per annum across two phases, with operations expected to commence in early 2027. Cash and marketable securities closed at $80.0 million at 30 June 2026, down from $100.4 million a year earlier, a reduction of $20.4 million reflecting $25.7 million of earn-out payments, $12.6 million of Cosette transaction and litigation costs net of $14.4 million in recovered costs, $8.1 million of discontinued operations outflows, and $8.4 million of capital leases, net capex and other items. Underlying EBITDA of $34.2 million represented a 7.9% increase on the $31.7 million previously anticipated on 31 July, reflecting the company's decision to treat a portion of retention-related share-based expense as part of continuing operations adjustments. Conclusion. Mayne Pharma's FY26 results reflect a year shaped by disruption from the Cosette transaction process alongside deliberate investment in its Women's Health portfolio and the launch of its DistributeRx platform. While total revenue and underlying EBITDA both declined, the statutory return to profit, aided by a substantial non-cash earn-out reassessment gain, together with early growth signals from DistributeRx and continued momentum in BIJUVA and NEXTSTELLIS, form the basis of the company's stated commercial momentum heading into FY27. FAQs. Q: Did Mayne Pharma's revenue grow in FY26? A: No, FY26 revenue was $383.7 million, down 6% on FY25's $408.1 million. Q: Why did Mayne Pharma report a statutory profit in FY26? A: The company reported Net Profit After Tax of $31.2 million, a turnaround from a $90.1 million loss in FY25, driven primarily by a $125.6 million non-cash gain from an earn-out liability reassessment. Q: what is DistributeRx? A: DistributeRx is Mayne Pharma's direct-to-patient distribution platform launched in March 2026, which generated 62,000 total prescriptions in its first full quarter, up 63% on the prior comparative period. Q: Did Mayne Pharma's underlying EBITDA decline in FY26? A: Yes, underlying EBITDA fell 27% to $34.2 million, which the company attributed to disruption from the Cosette transaction process and increased Women's Health sales and marketing investment. Q: How did Mayne Pharma's cash position change during FY26? A: Cash and marketable securities fell to $80.0 million from $100.4 million, reflecting earn-out payments, Cosette transaction and litigation costs, and other capital outflows. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

ASX set for a sluggish start as Wall Street drifts; Qantas profit slumps. Staff writers Updated August 27, 2026 - 6:35am,first published 5:26am The Australian sharemarket is set for a flat open on yet another busy earnings season day, with Qantas and Wesfarmers among those having reported their results before the start of trading. ASX futures slipped 4 points to 9068 as of 7.59am AEST. The ASX lost 0.4 per cent on Wednesday as shock inflation figures put another interest rate hike on the table. Wall Street drifted through a quiet session overnight after a report said US inflation was also a bit worse than economists expected. Qantas said before the start of trading its profits have taken a hit as rising fuel costs outpaced the benefit of sustained demand for international travel. The airline posted a 13.8 per cent fall in underlying pre-tax profit of $330 million in the year to June. Underlying pre-tax profit is $2.06 billion, down from $2.39 billion in 2025. The company said its fuel bill jumped by over $600 million as it was hit hard by the ramifications of the Middle East conflict. Retail conglomerate Wesfarmers saw its sales rise 3.4 per cent to $47.3 billion, and net profits excluding significant items grow by 8.3 per cent to $2.9 billion. Bunnings showed the biggest sales growth, up 4.1 per cent to $20.4 billion; Kmart sales grew by 2.8 per cent to $11.75 billion; and Officeworks gained 3.7 per cent to $3.7 billion. The company said Bunnings boss Mike Schneider will retire in February next year, with chief customer officer Rachel McVitty set to take over the role. Healthcare giant Sigma said its sales jumped 15.5 per cent to $10.8 billion and profits climbed 22.3 per cent to $732.2 million in its first results after taking over the Chemist Warehouse pharmacy chain. Business was boosted by demand for weightloss drugs, which will also help lift sales by double digits again in the current year, the company said. Mayne Pharma said underlying earnings had slumped 27 per cent to $34.2 million in the year to June as its management was distracted by the $672 million takeover bid by US private-equity backed drugmaker Cosette, which was eventually blocked by Treasurer Jim Chalmers on national interest grounds. "The Cosette transaction process and subsequent legal matters placed real demands on management focus and caused general disruption," chief executive Aaron Gray said. On Wall Street overnight, yields in the bond market, the focus of Wall Street's biggest recent worries, edged higher following America's inflation data, weighing on sentiment. The S&P 500 edged down by less than 0.1 per cent and remains near its all-time high set earlier this month. The Dow Jones Industrial Average dipped 113 points, or 0.2 per cent, and the Nasdaq composite slipped 0.1 per cent. Nvidia, the chipmaker at the heart of the artificial intelligence boom, delivered a sales forecast that met expectations. Its shares were up 4.3 per cent in after-hours trade. From our partners. Revenue in the current period will be $US108 billion, plus or minus 2 per cent, the company said in a statement. Though analysts had forecast $US105.2 billion on average, some projections exceeded $US110 billion, according to data compiled by Bloomberg. Stocks made relatively few big moves ahead of the earnings report from Nvidia, which arrived after trading ended for the day. Expectations were high once again for the chip giant, whose tremendous growth in profit because of the artificial-intelligence boom has made it the largest stock by value in the US market. Strong profit growth across US companies broadly has been the main reason the US stock market has run to records this year. Abercrombie & Fitch leaped 35.7 per cent after reporting a stronger profit for the latest quarter than analysts expected. The retailer also raised its forecast for earnings over the full year and for how much cash it will send to investors by buying back shares of its own stock. On the losing end of Wall Street was Intuit, even though the company behind TurboTax, Credit Karma and QuickBooks topped analysts' profit expectations in the latest quarter. It fell 3.2 per cent after giving a forecast for profit growth of nearly 25 per cent in its upcoming fiscal year, which fell short of analysts' expectations. Outside of earnings reports, Meta Platforms added 1.1 per cent after agreeing to pay up to $US18 billion ($24 billion) and to add child-safety measures to Facebook and Instagram to end a landmark trial over teen social media addiction and settle claims filed by states across the country. In the bond market, US Treasury yields ticked higher to 4.65 per cent from 4.64 per cent late on Tuesday following updates on inflation and economic growth. Yields had shot upward through the American summer on worries about high inflation and the US government's growing and gargantuan debt, among other factors. They got so high that the US Treasury Department made a surprise announcement last week to intervene in the bond market, though analysts say its effect could be limited. The latest update on inflation released overnight said that the measure the Federal Reserve has historically preferred to use sat at 3.7 per cent last month. That was the same rate of inflation as in June and slightly worse than the 3.6 per cent that economists expected, according to FactSet. It remains far worse than the 2 per cent goal the Fed has set. Growth in spending by US consumers, which is the main engine of the economy, slowed at the same time. The overall economy grew at a 1.5 per cent annual pace in the spring, according to a revised estimate of its performance, the same amount as the government's first estimate. Traders didn't change their forecasts much for what the Federal Reserve will do with its main interest rate in the short term, and they are betting on a nearly three-in-four chance the Fed will hike the federal funds rate at least once by the end of the year, according to data from CME Group. One of the factors that's worsened inflation this year is higher oil prices, though they've come down recently. The price for a barrel of Brent crude, the international standard, continued to swing Wednesday on uncertainty about when the war with Iran will allow oil tankers to freely exit the Persian Gulf again. It dropped as low as $US84.56 before settling at $US86.94. That's down 0.4 per cent from the day before and from $US94 at the end of last week. In other international markets, indexes rose across much of Europe and Asia. South Korea's Kospi climbed 1 per cent, and Japan's Nikkei 225 rose 0.6 per cent for two of the bigger moves. With AP, Bloomberg

Mayne Pharma appoints new Chief Financial Officer. 2.92 0.00 (0.00%) ASX Announcement MAYNE PHARMA APPOINTS NEW CHIEF FINANCIAL OFFICER 17 July 202 6, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces the appointment of Mr Griffin D. Buchanan as Chief Financial Officer (CFO) of the Company, effective 1 August 2026. Mr Griffin D. Buchanan is a senior finance executive with extensive experience in global medical technology and healthcare. He joins Mayne Pharma from Establishment Labs (NASDAQ: ESTA), a global medical technology company focused on women's health, where he served as Vice President, Operational Finance, leading financial planning, analysis and operational performance across the business. His appointment brings directly relevant sector experience to Mayne Pharma at a time when Women's Health remains a core p illar of the Company's portfolio. Prior to Establishment Labs, Mr Buchanan spent over 19 years at Siemens Healthineers (SH L:DE), one of the world's leading medical technology companies, where he held a series of senior finance leadership roles. As VP of Finance ( country, business line CFO) for its Enterprise Services business, he held P&L, balance sheet and cash flow accountability for a business generating approximately US$1.4 billion in annual revenue. Mr Buchanan holds an Executive MBA from Friedrich - Alexander - Universität Erlangen - Nürnberg and a Bachelor of Science, Business Administration, Information Technologies & Operations from the University of New Hampshire's Peter T. Paul College of Business and Economics. Mr Aaron Gray, CEO of Mayne Pharma said " We are delighted to welcome Griffin as Mayne Pharma's new CFO. Griffin's appointment strengthens our leadership team with a finance executive who understands the global medical technology and women's health markets first - hand. His experience optimising large, complex healthcare businesses aligns closely with Mayne Pha rma's priorities, and I look forward to working with him on executing our business objectives." For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 [email protected] Authorised for release to the ASX by the Board of Directors. Email Alerts To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor - relations/email - alerts/ Follow Listcorp Pty on LinkedIn ASX Announcement Page 2 About Mayne Pharma Mayne Pharma is an ASX - listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40 - year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com. Mayne Pharma Group Limited (ASX:MYX) is a pharmaceutical company focused on applying its drug delivery expertise to commercialise branded... MYX Profile Links MYX Information Share Price: 24hr Change: 24hr Change %: Market Cap: Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more. 05 Jun 2026 22 May 2026 29 Apr 2026